ArticleBMC cardiovascular disorders2024
The prevalence of implantable cardioverter-defibrillator (ICD) and heart failure patients eligible for remote monitoring in Germany.
Article in BMC cardiovascular disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Heart Failure in Lebanon: A Glimpse into the Reality of Growing Burden.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn Germany, contemporary data on the prevalence of patients with an implantable cardioverter-defibrillator (ICD) is lacking. Recently, ICD patients with heart failure (HF) fulfilling pre-defined criteria by the G-BA (Federal Joined Committee) are eligible for remote monitoring (RM) reimbursement. This investigation aims to evaluate the prevalence of HF patients with an ICD meeting these criteria.
methodsAnnual national quality assurance data from all German hospitals on newly implanted ICDs, New York Heart Association (NYHA) class and left ventricular ejection fraction (LVEF) between 2010 and 2021 were obtained to build a prevalence model. The number of ICD patients eligible for RM was calculated by applying the main G-BA inclusion criteria.
resultsThe ICD prevalence increased continuously from 2010 to 2017 (202.637 patients in 2017) and decreased with a lower rate until 2022. The model calculated an ICD prevalence of 190.698 patients in 2022 of which an estimated 120.941 ICD patients with HF were eligible for RM. This reflects approximately 63% of the actual total estimated ICD patient population in Germany.
conclusionsThe model identified a large patient population currently eligible for RM. To our knowledge, this is the first study providing information on the size of this ICD patient population with HF in Germany. With only a fraction of eligible patients currently receiving RM, these findings may facilitate future planning, resource calculations and scale-up of RM. The building of a specific infrastructure focussing on efficient use of resources reflects a mandatory prerequisite for successful RM implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.